Canaveral Medicines, Inc.

Biological preparations, namely, nucleic acids, proteins, and peptides for human and veterinary use; Chemical and biological diagnostic preparations and substances for clinical and medical laboratory use in drug discovery and nucleic acid and protein therapeutics in the bio-pharmaceutical industry; Nucleic acid-protein conjugates; Nucleic acids for medical purposes; Nucleic acids for scientific purposes; Nucleic Acid therapeutics; nucleic acid and protein therapeutics, namely, proteins designed to deliver highly targeted therapeutic modulation for patients suffering from a variety of diseases; Pharmaceutical preparations, namely, nucleic acid and protein therapeutics; Pharmaceuticals using protein biotherapeutics to treat human diseases; Pharmaceutical preparations containing nucleic acid and protein therapeutics for the treatment of immune system, infectious disease, pulmonary diseases and disorders, genetic diseases, metabolic diseases, kidney diseases, reproductive disorders, gastrointestinal diseases, cancers, and obesity; Protein therapeutics.; Biotechnology, medical and scientific research, and development services in the field of nucleic acid and protein therapeutics and diagnostics; Biotechnology research services, namely, nucleic acid and protein therapeutics development for applications in the lung, pediatric, gastrointestinal, reproductive, kidney, metabolic, infectious disease, cancer, immunological, and genetic disciplines; Medical and scientific research and development services in the field of nucleic acid and protein therapeutics and diagnostics; Research and development of medicines; Pharmaceutical research and development services in connection with nucleic acid and protein therapeutics.

Biological preparations, namely, nucleic acids, proteins, and peptides for human and veterinary use; Chemical and biological diagnostic preparations and substances for clinical and medical laboratory use in drug discovery and nucleic acid and protein therapeutics in the bio-pharmaceutical industry; Nucleic acid-protein conjugates; Nucleic acids for medical purposes; Nucleic acids for scientific purposes; Nucleic Acid therapeutics; nucleic acid and protein therapeutics, namely, proteins designed to deliver highly targeted therapeutic modulation for patients suffering from a variety of diseases; Pharmaceutical preparations, namely, nucleic acid and protein therapeutics; Pharmaceuticals using protein biotherapeutics to treat human diseases; Pharmaceutical preparations containing nucleic acid and protein therapeutics for the treatment of immune system, infectious disease, pulmonary diseases and disorders, genetic diseases, metabolic diseases, kidney diseases, reproductive disorders, gastrointestinal diseases, cancers, and obesity; Protein therapeutics.; Biotechnology, medical and scientific research, and development services in the field of nucleic acid and protein therapeutics and diagnostics; Biotechnology research services, namely, nucleic acid and protein therapeutics development for applications in the lung, pediatric, gastrointestinal, reproductive, kidney, metabolic, infectious disease, cancer, immunological, and genetic disciplines; Medical and scientific research and development services in the field of nucleic acid and protein therapeutics and diagnostics; Research and development of medicines; Pharmaceutical research and development services in connection with nucleic acid and protein therapeutics.